新辅助立体定向放射外科治疗脑转移瘤的国际合作:INTERNEO个体患者数据汇总分析
该汇总分析纳入5国9家机构179例患者共189个脑转移瘤,评估新辅助立体定向放射外科的疗效与安全性。中位随访28.4个月,12个月复合终点(局部复发、任意级别放射性坏死和/或结节型软脑膜病变)发生率为8.0%。结论认为新辅助立体定向放射外科在局部复发、放射性坏死和结节型软脑膜病变方面取得有利的发生率。
要点
- 179例患者189个脑转移瘤接受新辅助立体定向放射外科,中位随访28.4个月。
- 12个月局部复发率4.6%、任意级别放射性坏死3.6%、≥2级放射性坏死1.8%、结节型软脑膜病变1.2%。
- 12个月复合终点(局部复发、任意级别放射性坏死和/或结节型软脑膜病变)发生率为8.0%。
核心结论
- 新辅助立体定向放射外科在局部复发、放射性坏死和结节型软脑膜病变方面取得有利的发生率。
- 作者提供了该治疗方法的全球经验、长期数据以及接受多分次立体定向放射外科的最大队列。
研究设计与样本
- 个体患者数据汇总分析,纳入5个国家(澳大利亚、加拿大、韩国、瑞士和美国)9家机构接受单分次和多分次新辅助立体定向放射外科的脑转移瘤患者。
- 纳入标准为任何原发恶性肿瘤的脑转移瘤且无既往局部治疗,共179例患者189个脑转移瘤。
- 主要终点为局部复发、任意级别放射性坏死和/或结节型软脑膜病变的复合终点,次要终点包括上述各终点及≥2级放射性坏死,采用累积发生率函数评估。
主要发现
- 原发恶性肿瘤包括非小细胞肺癌(44%)和黑色素瘤(17%)。
- 脑转移瘤中位直径为29 mm(IQR 21-36 mm)。
- 单分次和多分次新辅助立体定向放射外科分别用于100个(53%)和89个(47%)脑转移瘤。
- 单分次中位剂量为18 Gy(IQR 16-20 Gy);多分次剂量包括24 Gy分3次(55%)和27 Gy分3次(25%)。
- 12个月复合终点发生率为8.0%;12个月局部复发率4.6%、任意级别放射性坏死3.6%、≥2级放射性坏死1.8%、结节型软脑膜病变1.2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Neoadjuvant stereotactic radiosurgery (NaSRS) is an emerging treatment option for brain metastases (BrM) planned for resection. The aim of this study was to report on the efficacy and safety of NaSRS in an individual patient data pooled analysis. MATERIALS AND METHODS: Patients undergoing single- and multi-fraction NaSRS for BrM at nine institutions in five countries (Australia, Canada, South Korea, Switzerland and USA) were included. Eligibility criteria included BrM from any primary malignancy and no prior local therapy. The primary endpoint was a composite of local recurrence (LR), any grade radionecrosis (RN), and/or nodular leptomeningeal disease (nLMD). Secondary endpoints included these endpoints and Grade ≥ 2 RN. Endpoints were evaluated using cumulative incidence functions. RESULTS: NaSRS was delivered to 179 patients with 189 BrM. Median follow-up was 28.4 months. Primary malignancies included non-small cell lung carcinoma (44 %) and melanoma (17 %). The median BrM diameter was 29 mm (IQR 21-36 mm). Single- and multi-fraction NaSRS was utilised in 100 (53 %) and 89 BrM (47 %) respectively. The median single-fraction dose was 18 Gy (IQR 16-20 Gy). Multi-fraction doses included 24 Gy in three fractions (55 %) and 27 Gy in three fractions (25 %). The 12-month incidence for the composite endpoint was 8.0 %. The 12-month incidence of LR was 4.6 %, any grade RN was 3.6 %, Grade ≥ 2 RN was 1.8 % and nLMD was 1.2 %. CONCLUSION: Neoadjuvant SRS results in favourable rates of LR, RN and nLMD. We provide a global experience of this treatment approach with long-term data and the largest cohort of patients undergoing multi-fraction SRS.
引用
- Udovicich C, Koo K, Michael Bryant J, et al. International collaboration of neoadjuvant stereotactic radiosurgery for brain metastases: The INTERNEO individual patient data pooled analysis. Radiother Oncol. 2024. PMID: 39579871. doi:10.1016/j.radonc.2024.110641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。